anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A composition and method for simultaneously lightening and coloring hair. The composition generally consists of three components, specifically, a bleaching composition, an oxidizing composition and a dyeing composition. The composition preferably lightens hair color by a plurality of levels and simultaneously deposits tones that are attractive and long lasting. In a preferred embodiment, the bleaching composition is a powder composition based on silicate and/or carbonate salts and/or persulfate salts of ammonium, potassium or sodium. The persulfate bleaching composition can be ammonia-free, if desired. The oxidizing composition is preferably an anhydrous hydrogen peroxide solution, or another source of oxygen. The bleaching composition can be mixed with the oxidizing composition to form an anhydrous creme that is applied to the hair.
An herbal tea product is provided to provide relief from lung and breathing conditions such as asthma. The herbal tea product may include oregano, peppermint, OSH A root, lungwort, eucalyptus, plantain leaf, chaparral, elecampane, lobelia, sage, licorice root, and thyme. The herbal ingredients may be included in equal amounts, such as (5) ounces. The OSH A root, elecampane, and/or licorice root may be crushed. Methods of making and using the herbal tea product are also disclosed. The herbal tea product may be placed into tea bags, and prepared for human consumption by placing the tea bag with herbal tea product in hot water that has been brought to a boil. The herbal tea product may be consumed in appropriate amounts, such as 16 ounces, twice a day for two weeks, and then once a day thereafter.
Pre-diabetic participants will receive general health guidelines according to the NICE guidelines, as per standard care. These will be delivered via an initial consultation with a dietitian. Participants in the control group will receive 2 follow up phone calls from the dietitian to answer any questions they may have during the study.
The present invention provides a inhalation-type pharmaceutical composition for treating hypertension and preparation method thereof. The first gas includes hydrogen. In the inhalation-type pharmaceutical composition, A volume concentration of hydrogen is 2% to 96%. The atomized pharmaceutical composition is selected from a group including propranolol, captopril, amlodipine besylate, losartan, and a certain combination thereof. The inhalation-type pharmaceutical composition eliminates harmful radical in the patient′s body, and may increase the absorption by using the atomized pharmaceutical composition. At the same time, a side effect may be indirectly decreased due to using a small amount of evaporated fluid.
Only children admitted to the hospital with clinically detectable dehydration (weight loss, dry skin, sunken eyes, no tears) will be evaluated. Weight, noninvasive blood pressure measurement, pulse rate will be recorded. Measurements would be performed with an ultrasound probe with a low frequency (2-5 MHz), a curved array transducer will be used. In the supine position, the ultrasound probe will be placed in the substernal area, in the longitudinal and transversal plane, 1 cm caudal to the confluence of the hepatic veins, and it will be operated in M-mode. The largest (VCImax) and smallest (VCImin) diameters will be measured and the collapsibility index will be calculated (according to the formula: VCImax - VCI min / VCI max x100). Immediately after this examination measurement of the right VJImax, min and the left VJImax, min will be measured again in the supine position, then after passive leg raise (lifting the lower limbs 45st. for at least 1minute ) VJImax, min. and left VJImax, min will be measured. The collapsibility index for right and left VJI would be calculated according to the formula: VJImax - VJI min / VJI max x100. After a defined fluid infusion (20ml/kg, but the maximum volume will be limited to 500ml, this means that over 25kg weight we would apply not more than 500ml) within 60 minutes. A control examination of VCI, right VJI, and left VJI will be evaluated the same way as first and compared with the previous one.
The present invention relates to a composition for a primary tooth crown, an antibacterial primary tooth crown using the same, and a manufacturing method for the same. According to the present invention, the composition for a primary tooth crown includes: 30-50 wt% of poly lactic acid (PLA); 10-30 wt% of poly ε-caprolactone (PCL); 3-20 wt% of a compatibilizer; 0,5-2 wt% of zirconia (ZrO_2); and 10-30 wt% of an inorganic filler. According to the present invention, the composition for a primary tooth crown has a relatively excellent thermoform property, reduced brittleness, and relatively high rigidity while having excellent bio compatibility. The composition for a primary tooth crown has an excellent sustained-releasing property of an antibacterial substance and is useful for the formation of an antibacterial primary tooth crown. According to the present invention, the antibacterial primary tooth crown sustainably releases a natural antibacterial substance and suppresses proliferation of harmful bacteria in a mouth. So, the composition for a primary tooth crown effectively prevents oral cavity diseases and protects primary teeth. The composition for a primary tooth crown is harmless and has a high degree of bio compatibility, rigidity, and aesthetic impression, as well as reduced fragility. Also, the composition for a primary tooth crown can easily perform a shade guide that is actually the same color as that of a natural primary tooth.
The invention relates to a process for preparing a dental material filler in the form of a copolycondensate. An alkoxy silane having a formula of Si(OR 3 ) 4  and a titanium compound are dissolved in a water-miscible solvent. Optionally, additional alkoxysilanes having the formulas R 1  --Si(OR 3 ) 3  and R 2   2  Si(OR 3 ) 2  are also dissolved in the solvent. The reactants are hydrolyzed and condensed to form a reaction mixture from which a heterosiloxane is formed. The heterosiloxane is separated, optionally washed, dried and tempered. The heterosiloxane may then be ground to a desired size and/or formed into various dental materials, such as fillings, inlays, veneers, seals, crowns, bridges, dentures, artificial teeth and adhesives for dental materials. Alternatively, the reaction may take place without the use of a water miscible solvent, such that the precondensing takes place in water.
Provided is a more effective dental synbiotic lozenge that is intra-orally adhesive. The lozenge contains adhesive prebiotics and excipients, and one or more species of probiotic organisms. While safely adhered to an intra-oral surface, the lozenge dissolves to provide a controlled time-release of the excipients, prebiotics, and probiotic organisms over a period of hours instead of minutes. The lozenge dissolves into a malleable biofilm that includes a natural biofilm formed by the prebiotics and a supplemental biofilm formed by the excipients. The lozenge can be used while sleeping, which can increase probiotic availability exponentially. The result is a lozenge that allows for a smaller, but more diverse, microbial payload that can grow over time such that a fewer number of organisms are needed from the start. In one embodiment, the lozenge contains adhesive prebiotics acacia and inulin, along with additional excipients microcrystalline cellulose, HPMC K15, and sodium alginate.
BACKGROUND: Acute appendicitis is a common cause of acute abdominal pain necessitating surgical intervention. While the traditional treatment has been urgent appendectomy, recent studies suggest that an antibiotics-first approach can be safe for uncomplicated cases. Classifying appendicitis into uncomplicated and complicated categories is crucial for guiding treatment decisions and predicting patient outcomes. This study aims to evaluate the distinct imaging findings associated with uncomplicated appendicitis and its complicated subtypes-phlegmonous, gangrenous, and perforated appendicitis-to aid in differential diagnosis.
METHODS: This retrospective observational study was conducted from January 2014 to December 2023 and included 1,250 patients (492 women, 758 men) who underwent an appendectomy with available pathology results. After excluding 56 patients with normal pathology, 52 with non-appendicitis pathologies, and 48 with inaccessible computed tomography (CT) images, 1,094 patients were analyzed. CT images were evaluated for appendiceal diameter, wall thickness, cecal wall thickness, periappendiceal fat stranding, effusion, lymphadenopathy, intraluminal and free periappendiceal air, mucosal hyperenhancement, and the presence of appendicolith.
RESULTS: The diameter of the appendix, along with the presence of periappendiceal air, effusion, and intraluminal appendicolith, were significantly higher in the perforated appendicitis group compared to other groups (p<0.05). Periappendiceal fat stranding, evaluated as a binary variable, did not show significant differences among the groups. Appendiceal wall thickness was higher in the perforated group and lower in the non-perforated gangrenous group compared to the uncomplicated group (p<0.05). No significant correlation was found for mucosal hyperenhancement between the appendicitis subgroups. Intraluminal air, though normal in a healthy appendix, was a specific predictor of complicated appendicitis when combined with other findings.
CONCLUSION: This study provides a detailed analysis of distinct imaging findings associated with uncomplicated and complicated appendicitis. Key differentiators such as appendiceal diameter, periappendiceal air, effusion, and intraluminal appendicolith are crucial for accurate diagnosis. The findings highlight the importance of these parameters in distinguishing various types of appendicitis, offering valuable insights for clinical practice. Future prospective studies and advanced imaging techniques are needed to validate these findings and enhance the diagnosis and management of acute appendicitis and its complications.
CONTEXT: Bacillus Calmette-Guérin (BCG) vaccine has been used to prevent tuberculosis and/or its severe complications for long. BCG lymphadenitis is a common complication of the vaccine, which is sometimes subjected to cytological examination. The aim of the study is to describe the cytological findings of BCG lymphadenitis.
SETTINGS: The study was conducted in a tertiary care hospital in the western part of India from January 2021 to December 2022.
DESIGN: The study was performed on archived material of all patients who were referred to the fine needle aspiration clinic for cytology examination. Clinical and pathological data of cases were retrieved, and cases of BCG lymphadenitis were selected in the study based on these data. Slides of cases were retrieved, and cytological findings were studied.
MATERIALS AND METHODS: Papanicolaou, Giemsa, and Hematoxylin & eosin-stained smears, as well as Ziehl-Neelson stain (Z.N. stain) smears of all BCG lymphadenitis cases, were retrieved. Cases were reviewed for individual cytological features and overall cytological diagnostic categories. Z.N. stain smears were evaluated for acid-fast bacilli.
RESULTS AND CONCLUSIONS: Diagnostic categories observed in BCG lymphadenitis include suppurative lymphadenitis/abscess (15 %), necrotizing lymphadenitis (23 %), necrotizing granulomatous lymphadenitis (46 %), suppurative granulomatous lymphadenitis (8 %), non-necrotizing granulomatous lymphadenitis (8 %). Acid-fast bacilli were detected by Z.N. stain in 8 cases (62 %). The cytological findings of BCG lymphadenitis closely overlap with those of tuberculous lymphadenitis. So, clinical context is very important while reporting isolated axillary lymphadenopathy, specifically in recently vaccinated infants, to avoid misdiagnosis as tuberculous lymphadenitis.
Patients referred with a confirmed diagnosis of patellofemoral pain syndrome, with a visual analogue scale of more than 3. Anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
Each participant will stay in the calorimeter (\~24 hrs) on 2 different occasions. During the second visit, the participant will partake in a guided exercise session.
For study 1, exercise endurance time and heart rate recovery will be measured after arm ergometry without stimulation. For study 2, body core temperature and thermal comfort will be reported without stimulation.
Mahmood Green Tea Sri Lanka. It will be given 2 cups / day for 30 days.
A pharmaceutical composition for preventing and treating arteriosclerosis, which contains an Elsholtzia splendens extract is provided to reduce neutral lipid, low density cholesterol, and atherosclerotic index, increase alpha-tocopherol and prolong the initial delay time of low density cholresterol. An Elsholtzia splendens extract is obtained by extracting a flower with ethanol, methanol, propanol, chloroform or acetone. The Elsholtzia splendens extract is obtained by drying the flower, pulverizing, adding ethanol to pulverized sample and maintaining at a room temperature. A pharmaceutical composition for preventing and treating arteriosclerosis comprises the Elsholtzia splendens extract. The pharmaceutical composition is administered by oral or parenteral. A solid formulation for the oral administration of is a pill, tablet, powder, and capsule. A liquid formulation for oral administration is suspension..
BAKGROUND: Vitamin D (Vit D) deficiency is common in patients with hyperparathyroidism, but the importance of replacement before surgery is controversial. It can be predicted that hypocalcemia risk will be higher in patients with high bone turnover.
AIM: In this study, the effect of preoperative ALP/Vit D ratio on postoperative hypocalcemia was investigated.
METHODS: Among the primary hyperparathyroidism cases who were operated between 2015 and 2022, 158 patients with complete data were included in the study. Preoperative laboratory results, radiological images, and pathology reports of the patients were evaluated retrospectively. The cross-sectional value of the ALP/Vit D value predicting hypocalcemia was calculated. The effect of these parameters on postoperative hypocalcemia was investigated.
RESULTS: The mean age of our patients was 54 (21-81 years). When factors affecting postoperative hypocalcemia were evaluated by univariable analysis, Vit D deficiency and insufficiency (p < 0.001), ALP (p < 0.001), ALP/Vit D ratio (p < 0.001), and T score (p = 0.026) found to be factors affecting postoperative hypocalcemia. In multivariate analysis, the ALP/Vit D ratio was found to be an independent variable in predicting hypocalcemia. It was found that hypocalcemia was 45 times more common in patients with ALP/Vit D > 6.34 (p < 0.001). ALP/Vit D ratio predicts patients who will develop postoperative hypocalcemia with 87.2% sensitivity and 87.1% specificity.
CONCLUSIONS: Vit D deficiency increases the risk of postoperative hypocalcemia, but it is not sufficient alone to predict it. The risk increases more in patients with high bone turnover. The preoperative ALP/Vit D ratio is the strongest predictor of postoperative hypocalcemia risk.
ENLON is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis.

ENLON is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.
The study is non-concurrent, multiple-baseline, across-subjects, single-case research design (SCRD). The central hypothesis is that mantra meditation (independent variable) will be associated with improvement on 1 or more tests of behaviorally measured sustained attention (dependent variable). The mantra in this study is the syllable "um" and is not assigned any spiritual, religious, or affective meaning. The mantra is repeated aloud together by the subject and the PI for a duration of 30 minutes in each session. This procedure constitutes meditation for the purposes of this study. There are 9 session of meditation (3 times per week for 3 weeks). Attention is measured in each of these sessions as well as in 3 separate testing sessions that precede the intervention period.
To achieve maximum contraceptive effectiveness, oral contraceptives must be taken exactly as directed and at intervals not exceeding 24 hours.

For a DAY 1 START, count the first day of menstrual flow as Day 1 and the first light blue tablet is then taken on Day 1. For a SUNDAY START when menstrual flow begins on or before Sunday, the first light blue tablet is taken on that day. With either a DAY 1 START or SUNDAY START, 1 light blue tablet is taken for 7 days, then 1 light yellow-green tablet for 9 days, then 1 light blue tablet for 5 days, then 1 orange tablet (inert) for 7 days, whether bleeding has stopped or not. With either a DAY 1 START or SUNDAY START 1 tablet is taken each day at the same time for 28 days. After all 28 tablets are taken, whether bleeding has stopped or not, the same dosage schedule is repeated beginning on the following day.
A disclosed cell-energy skin-care liquid is a medicine for restoring intima and treating cervical erosion. The medicine is composed of the following raw materials in parts by weight: 10-20 parts of fructus cnidii, 10-20 parts of alum, 10-20 parts of radix sophorae flavescentis, 5-10 parts of sanguis draxonis, 10-20 parts of radix sanguisorbae, 10-20 parts of cortex phellodendri, and 1000-2000 mL of ethanol. The medicine is prepared according to the following method: mixing and crushing fructus cnidii, alum, radix sophorae flavescentis, galla chinensis, sanguis draxonis, radix sanguisorbae and cortex phellodendri, pouring the medicinal powder into ethanol, infusing for 15-20 days, and removing precipitates to obtain a liquid which is a finished product; and putting the finished product into a spray bottle with an elephant trunk. The liquid is wide in medicine source and low in price, and has the efficacy of eliminating dampness heat, removing dampness toxin, diminishing inflammation, repelling toxin, astringing and promoting tissue regeneration, and the like. By using the cell-energy skin-care liquid, mild cervical erosion can be healed within 5-7 days, moderate cervical erosion can be healed within 7-10 days, and severe cervical erosion can be healed within 10-20 days, and the therapeutic effect is substantial. Additionally, the cell-energy skin-care liquid is capable of effectively treating pruritus vulvae, drug hypersensitivity, acne and mosquito bites.
Water-soluble acetylated glucopeptides are prepd. from lysed Escherichia coli cells. They have a molecular weight of 1000-200,000 contain >=25% biuretogenic material and >=30% neutral monosaccharides. They do not contain diaminopimelic acid and having a UV absorption maximum at 210 mu. Glucoproteins or molecular wt. >300,000 extracted from lysed E. coli cells are submitted to acetolysis, usually with a mixt. of acetic anhydride acetic acid and sulphuric acid. The crude acetylated prod. is treated with an organic solvent, such as chloroform, and the aq. phase undergoes diafiltration using a porous membrane which retains material of mol. wt. >=1000. The retained material is sepd.
OnabotulinumtoxinA Dose A injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
PURPOSE:An investment material for dental casting, containing a ceramic, e.g. quartz glass, having increased density by heat-treating under high pressure as an investment material having a large amount of swelling in heating and a small amount of swelling in curing and a binder. CONSTITUTION:An investment material for dental casting,consisting of a high- density ceramic, e.g. quartz glass, and a binder, and obtained by hot-pressing the quartz glass at 10 GPa or below and 700 deg.C or below for 10min or less, cooling the resultant hot-pressed quartz glass to room temperature, and reducing the pressure to the ordinary pressure. Silicic acid may be further added to the resultant investment material, and therefore the shrinkage is reduced. Silicate glass consisting essentially of SiO2 glass and germanate glass consisting essentially of GeO2 or coesite, etc. may be used in addition to the quartz glass. EFFECT:Metallic molded articles of desired shape are obtained without requiring a means, e.g. absorbing or hardening swelling, etc.
PURPOSE: A medicine patch manufacturing apparatus is provided to have a simple manufacturing method without cutting a medicine part secondly, high yield rates due to no loss and to be easily separated due to embossing despite a fact that a medicine is leaked from the medicine part. CONSTITUTION: A medicine patch manufacturing apparatus is packed with a single medicine patch which comprises medicine for an external use. The medicine supplies a pharmacologically active compound to skin. The medicine patch manufacturing apparatus comprises a medicine patch manufacturing unit, a medicine transporting part(5), a medicine patch supplying and regaining part(6), a packing part(7), a final product loading part and a controlling part(9). The medicine patch treating part(4) coils a cloth with medicine(1a), forms a cutting line(122) on a different taped film(12) and makes a medicine part(1) by cutting the film. After cutting, discharged cloth from the medicine part is re-collected. A medicine part supplying and regaining part coils packing cloth(211), forms an embossing(26) on the packing cloth, provides upper packing cloth(212) with the embossing, provides lower packing cloth(221) with the embossing, and re-collects a discharged cloth(24) left from the packing cloth. A packing part wraps a medicine part with the upper packing cloth and the lower packing cloth to manufacture the medicine patch.
The \~200 group homes randomized into this arm will receive the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consists of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm will receive coaching specific to the setting, staff, and residents.
Participants randomized to this arm received Fluticasone propionate/salmeterol combination product 250/50 mcg, formulated with lactose via the DISKUS inhaler one inhalation BID, one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication.